Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Conclusions:
Ezetimibe improved FRS whereas placebo did not. FRS and CAC scores improved in a greater proportion of patients with ezetimibe; this trend did not reach significance. These findings indicate the utility and feasibility of monitoring cardiovascular risk in a NASH trial. The utility of CAC scores may be higher in trials of longer duration (>=52 weeks) and with older patients (age >=45).
ClinicalTrials.gov registration: NCT01766713.

Source: Therapeutic Advances in Gastroenterology - February 8, 2016 Category: Gastroenterology Authors: Lin, S. C., Ang, B., Hernandez, C., Bettencourt, R., Jain, R., Salotti, J., Richards, L., Kono, Y., Bhatt, A., Aryafar, H., Lin, G. Y., Valasek, M. A., Sirlin, C. B., Brouha, S., Loomba, R. Tags: Original Research Source Type: research